CERO Therapeutics Holdings, Inc. announced on June 11, 2025, that its board of directors has determined to effect a one-for-twenty reverse stock split of the company’s common stock. This corporate action is scheduled to take effect at 12:01 a.m. Eastern Time on June 13, 2025.
Upon the effectiveness of the reverse stock split, every twenty issued shares of common stock will be combined into one issued share. This will reduce the number of outstanding shares of common stock from approximately 10,321,839 shares to approximately 516,092 shares.
Proportional adjustments will be made to shares available under equity incentive plans, as well as the exercise price and number of shares issuable upon exercise or conversion of outstanding stock options and other equity securities. The company's common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on June 13, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.